What is the Org number of IMMUNOPHARMA AS?

IMMUNOPHARMA AS is registered with Brønnøysundsregistrene under Org 994924273.

What is the revenue of IMMUNOPHARMA AS?

IMMUNOPHARMA AS reported revenue of NOK 12,2B in 2024.

IMMUNOPHARMA AS employs 16 people as of the latest annual report.

Knut Christian Espeseth is the CEO of IMMUNOPHARMA AS, in role since 2024.

Kjetil Ramsøy chairs the board of IMMUNOPHARMA AS, in role since 2021.

IMMUNOPHARMA AS's registered address is Mustads Vei 1A, 0283 Oslo.

ASActive

Org 994924273Mustads Vei 1A, 0283 OsloActivities of advertising agencies· NACE 7311Est. 2010 · 16 years old16 employeeswww.immunopharma.net

Actively employed in the business

Name	Role	Member since
Current (2)
KC Knut Christian Espeseth Chief Executive Officer	Chief Executive Officer	2024
PJ Piotr Jerzy Sierdzinski Deputy Member	Deputy Member	2026
Former (2)
RS Ralf Schmidt Chief Executive Officer	Chief Executive Officer	2021 – 2022
GH Geir Hetland Deputy Member	Deputy Member	2020 – 2021

Non-executive oversight

Name	Role	Member since
Current (3)
FM Frode Marc Bohan Board of Directors	Board of Directors	2021
KØ Kim Øien Board of Directors	Board of Directors	2021
KR Kjetil Ramsøy Chairman	Chairman	2021
Former (1)
KZ Katarzyna Zdzislawa Maresz Board of Directors	Board of Directors	2020 – 2021

As of last annual report

Shareholder	Type	Ownership	Votes	Since
Bohan & Co As	Company	35.45%	35.45%	2025
Nicoline Invest As	Company	28.9%	28.9%	2025
Equity Labs Sp. Z.O.O Ska	Company	5.91%	5.91%	2025
Six Sis Ag	Company	5.3%	5.3%	2025
Ubs Switzerland Ag	Company	3.72%	3.72%	2025
Nordic Healthy Living As	Company	1.93%	1.93%	2025
Pro As	Company	1.6%	1.6%	2025
Theo Investments As	Company	1.55%	1.55%	2025
Noxa As	Company	1.44%	1.44%	2025
Vestmark Research Consulting As	Company	1.44%	1.44%	2025
3lp Norge As	Company	1.24%	1.24%	2025
Rhumb Line As	Company	1.22%	1.22%	2025
Avanza Bank Ab	Company	1.02%	1.02%	2025

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.